Fig. 6
Mechanism of in vivo antitumor efficacy. The percentages of CD3+CD4+ T cells in primary tumors (a) and distant tumors (b) after intravenous injection of nanoagonists into mice with or without treatment of NIR-II laser (1 W/cm2) for 10 min. The percentages of CD3+CD8+ T cells in primary tumors (c) and distant tumors (d) from different treated mice. e Immunofluorescence staining images of CD4 and CD8 (red fluorescence signals) in primary and distant tumors. Serum levels of IL-6 (f), IFN-γ (g) and TNF-α (h) after different treatments of mice